neuregulin inhibitors (CeNeS/Repligen)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameneuregulin inhibitors (CeNeS/Repligen)
Drug Alias Nameneuregulin inhibitors (Cambridge Neuroscience/Repligen)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonistsReceptor protein-tyrosine kinase erbB-4 antagonists +[4] 
TargetsNeuregulinsReceptor protein-tyrosine kinase erbB-4Receptor tyrosine-protein kinase erbB-3 +[4] 
Therapy Area/IndicationsBrain NeoplasmsOvarian NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCeNeS Pharmaceuticals plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCeNeS Pharmaceuticals plcRepligen Corp
Active IndicationsN/A
Inactive IndicationsBrain NeoplasmsOvarian NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A